UNSPSC 51112004: Gefitinib

This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H24ClFN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S65743JHBS, chemically known as 4-quinazolinamine, n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)- but generally known as gefitinib, which bears US NIH Compound Identifier 123631. European Medicines Agency schedules Gefitinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20637.

UNSPSC 51112004 Gefitinib, a Commodity code, encompasses state and local procurement of branded and generic pharmaceutical products, particularly oncology medications and specialty drugs distributed through established pharmaceutical supply chains. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively solicits manufacturers and wholesalers supplying generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities. Issuing bodies under this code include state health departments, cooperative purchasing alliances spanning multiple states, and subordinate local government health and human services agencies. The code captures both direct manufacturer relationships and distribution agreements with authorized wholesalers such as AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with vendors required to maintain compliance certifications including current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA).

MMCAP's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, represents the most recent significant activity under this code. The solicitation seeks manufacturers to provide comprehensive pricing for identified pharmaceutical products with specific National Drug Codes (NDC), requiring detailed product information and pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. All products must be available in the marketplace by May 15, 2026, with resulting contracts effective July 1, 2026 for a two-year initial term with optional extensions. Evaluation weighs price competitiveness most heavily (75 percent), followed by fixed pricing for the contract term (10 percent), compliance with data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain insurance coverage including commercial general liability of five million dollars per occurrence and network security and privacy liability of two million dollars, with performance penalties ranging from two hundred to fifteen hundred dollars per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.